Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting appointments on the non-profit side.

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...